Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4779286 | 0.87 | KMT2A (0.50) | AXLPDGFRBPDGFRAKDM4EMEN1 | |
| SCHEMBL9316760 | 0.80 | MTNR1A (0.54) | AXLPDGFRBPDGFRALOXL2KDM4E | |
| SCHEMBL17030590 | 0.78 | PDGFRB (0.41) | PDGFRBPDGFRAKDM4EMEN1KMT2A | |
| SCHEMBL14845700 | 0.77 | LOXL2 (0.47) | PDGFRBPDGFRALOXL2KDM4EMEN1 | |
| SCHEMBL30627124 | 0.77 | CA2 (0.44) | PDGFRBPDGFRAKDM4EMEN1KMT2A | |
| SCHEMBL3216438 | 0.74 | KDM4E (0.46) | KDM4EMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL1465598 | 0.74 | CYP2A6 (0.52) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL13334409 | 0.73 | KIF11 (0.40) | ALDH1A1HSD17B10HPGDALOX15HRH4 | |
| SCHEMBL12826974 | 0.73 | KDM4E (0.42) | KDM4EMEN1KMT2AMAPTNPC1 | |
| SCHEMBL5358725 | 0.73 | MEN1 (0.44) | AXLPDGFRBPDGFRAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334275-B2 | Processes for preparing indoles | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-05-10 | — | — | US | disclosed |
| US-9334275-B2 | Processes for preparing indoles | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-05-10 | — | — | US | disclosed |
| US-20150005494-A1 | PROCESSES FOR PREPARING INDOLES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2015-01-01 | — | — | US | disclosed |
| US-20150005494-A1 | PROCESSES FOR PREPARING INDOLES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2015-01-01 | — | — | US | disclosed |
| US-8680120-B2 | Indole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-8680120-B2 | Indole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| WO-2013095304-A1 | PROCESSES FOR PREPARING INDOLES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2013-06-27 | — | — | WO | disclosed |
| EP-2460791-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20100061982-A1 | 3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2009155042-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155042-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | disclosed |
| US-6252084-B1 | THERAPY FOR SEPSIS SHOCK | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0620215-B1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | LILLY CO ELI (US) | 1999-08-18 | — | — | EP | disclosed |
| US-5684034-A | INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE | ELI LILLY AND COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005494-A1 | PROCESSES FOR PREPARING INDOLES | IDO1, INMT, IDO2 | AXL 3157/4885PDGFRB 1894/4885PDGFRA 1540/4885 |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PDPK1 | AXL 1160/4885PDGFRB 973/4885PDGFRA 1027/4885 |
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, ARRB1 | AXL 2016/4885PDGFRB 310/4885PDGFRA 661/4885 |
| US-20100061982-A1 | 3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PDPK1, RICTOR | AXL 730/4885PDGFRB 437/4885PDGFRA 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.